Glutathione reductase (GSR) is the enzyme that closes the glutathione antioxidant cycle: it uses NADPH and the cofactor flavin adenine dinucleotide (FAD, derived from riboflavin/vitamin B2) to regenerate reduced glutathione (GSH) from oxidized glutathione (GSSG). Without functioning GSR, oxidative damage accumulates wherever GSH is the primary defense — including the highly metabolically active hair cells of the cochlea.

rs2251780 is an intronic variant in the GSR gene on chromosome 8 (8p12). The minor A allele is present in roughly 20% of the global population and has been classified as benign¹¹ benign
dbSNP ClinVar RCV001707149 by ClinVar with respect to general disease risk. Its functional effect, if any, is not yet characterized at the protein level.

The Mechanism

Glutathione reductase²² Glutathione reductase
FAD-dependent flavoenzyme that regenerates GSH from GSSG requires riboflavin-derived FAD as an obligate cofactor. Each GSR monomer contains one tightly bound FAD molecule. Riboflavin deficiency measurably reduces GSR activity in erythrocytes — a relationship so reliable that the erythrocyte glutathione reductase activation coefficient (EGRAC) is the clinical gold-standard biomarker for assessing riboflavin (vitamin B2) status. An EGRAC ≥ 1.3 indicates biochemical riboflavin deficiency.

Because rs2251780 sits in an intron, it does not alter the GSR amino acid sequence. Intronic variants can, however, influence gene expression via splicing regulation, transcription factor binding, or chromatin accessibility effects — none of which have been functionally demonstrated for this specific SNP. The association with hearing loss recovery is therefore a candidate-gene signal, not a mechanistic proof.

The Evidence

A prospective study by Kitoh, Nishio & Usami (2017)³³ Kitoh, Nishio & Usami (2017)
Prognostic impact of gene polymorphisms in patients with idiopathic sudden sensorineural hearing loss. Acta Otolaryngol, 2017 screened 16 SNPs across 13 antioxidant and vascular genes in 192 Japanese patients with sudden sensorineural hearing loss (SSNHL) receiving standardized corticosteroid therapy. GSR rs2251780 and a second GSR SNP (rs3779647) reached statistical significance (p<0.05) as predictors of poor hearing recovery. NOS3 rs1799983 (endothelial nitric oxide synthase) was co-associated. The study is small (n=192) and has not been independently replicated — evidence level is accordingly emerging.

A larger screen by Harris et al. (2007)⁴⁴ Harris et al. (2007)
A genetic association analysis of cognitive ability and cognitive ageing using 325 markers for 109 genes associated with oxidative stress or cognition. BMC Genetics, 2007 found no significant association between rs2251780 and any cognitive outcome across four cognitive tests in two independent cohorts (all p-values ≥0.23). This null result suggests the variant's phenotypic impact, if real, is narrow rather than a broad oxidative-stress signature.

Practical Actions

For AG or AA carriers, the primary practical lever is ensuring adequate riboflavin status, since GSR activity is directly coupled to FAD availability. Clinical riboflavin deficiency lowers measurable GSR activity, and supplementation restores it. Given the hearing-loss signal — even if preliminary — cochlear antioxidant reserve is the most plausible place this variant could matter.

Interactions

GSR rs2251780 was co-associated with NOS3 rs1799983 in the Kitoh 2017 hearing loss study, suggesting that combined impairment of cochlear antioxidant defense (GSR) and nitric oxide signaling (NOS3) may compound hearing vulnerability more than either variant alone. The mechanistic basis for this combination is plausible — both GSH and NO are reactive species whose cochlear balance is critical during acoustic trauma — but the combined effect has only been observed in one small study and requires replication before firm conclusions can be drawn.

Interleukin-17A (IL-17A) is the signature cytokine of Th17 cells¹¹ Th17 cells
a specialized subset of CD4+ T helper cells that drive inflammation at mucosal surfaces and in joints. Under normal conditions, Th17 cells defend against extracellular bacteria and fungi; when dysregulated, they become primary drivers of autoimmune inflammation in psoriasis, rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease. The rs2275913 (-197G>A) variant sits in the promoter of the IL17A gene and acts as a volume control for this entire inflammatory axis.

The Mechanism

The -197 position lies within a nuclear factor of activated T cells (NFAT) binding motif²² nuclear factor of activated T cells (NFAT) binding motif
NFAT is a transcription factor that, when active, drives IL-17A gene expression in stimulated T cells. The A allele increases the affinity of NFAT for this binding site compared to the G allele. When immune cells are activated — by infection, stress, gut dysbiosis, or autoimmune triggers — carriers of the A allele produce significantly more IL-17A than GG carriers. Reporter gene assays show the A allele construct has significantly higher luciferase activity than the G allele, especially under T-cell activation conditions. Electrophoretic mobility shift assays confirm that the A allele probe forms more intense protein-DNA complexes with NFAT than the G allele.

This variant location is also where vitamin D3 exerts its most direct effect on IL-17A. Active vitamin D (1,25-dihydroxyvitamin D3) represses IL-17A transcription by blocking NFAT at this exact binding site³³ Active vitamin D (1,25-dihydroxyvitamin D3) represses IL-17A transcription by blocking NFAT at this exact binding site
the vitamin D receptor competes with NFAT for occupancy at the -197 promoter element, recruits histone deacetylases, and sequesters Runx1. A allele carriers have enhanced baseline NFAT occupancy, making adequate vitamin D status particularly important for offsetting this elevated drive.

The Evidence

The functional consequences of increased IL-17A output have been documented across multiple diseases. In the largest functional study, PBMCs from A allele carriers secreted significantly higher IL-17 after stimulation, and donors with the A allele had a hazard ratio of 1.46 for acute graft-versus-host disease after unrelated bone marrow transplantation (Espinoza et al., PLoS ONE 2011, n=438 transplant pairs)⁴⁴ (Espinoza et al., PLoS ONE 2011, n=438 transplant pairs).

In ulcerative colitis, a Japanese case-control study of 202 UC patients and 475 controls showed the A allele minor allele frequency was significantly higher in cases, with the homozygous AA genotype conferring elevated UC risk, and combined rs2275913 AA / rs3748067 CC showing OR 3.38 (p=0.0007)⁵⁵ OR 3.38 (p=0.0007).

In ovarian endometriosis, a Chinese case-control study (316 patients, 328 controls) found AA genotype associated with OR 2.28 (95% CI 1.37–3.80) vs GG⁶⁶ AA genotype associated with OR 2.28 (95% CI 1.37–3.80) vs GG, with elevated IL-17A mRNA confirmed in ectopic endometrial tissue of AA carriers.

A 2023 meta-analysis of recurrent miscarriage found the AA genotype significantly associated with recurrent pregnancy loss (OR 1.68, 95% CI 1.13–2.49)⁷⁷ (OR 1.68, 95% CI 1.13–2.49).

For coronary artery disease, a case-control study showed the AA genotype conferred OR 2.42 (95% CI 1.26–4.54)⁸⁸ OR 2.42 (95% CI 1.26–4.54) for CAD development, with elevated serum IL-17A levels in cases.

Practical Actions

Three interventions specifically target the Th17/IL-17A axis and are relevant to A allele carriers:

Vitamin D3: Active vitamin D is the most direct molecular antagonist of the NFAT site where this variant acts. Maintaining serum 25(OH)D above 40 ng/mL (100 nmol/L) is the target for Th17 modulation. Most adults require 2,000–4,000 IU D3 daily to reach this level; those with dark skin, limited sun exposure, or VDR variants may need more. Test serum 25(OH)D to calibrate your dose.

EPA/DHA omega-3s: EPA suppresses Th17 polarization and reduces IL-17A production through prostaglandin D3 (PGD3), an EPA-derived metabolite that inhibits Th17 differentiation and promotes Treg expansion. Studies in psoriasis models show EPA normalizes keratinocyte hyperproliferation and reduces IL-17A output. Aim for 2–3 g combined EPA/DHA daily from fish oil or algae-based supplements.

Probiotics: Specific strains shift the Th17/Treg balance. Lactobacillus acidophilus, L. rhamnosus, L. delbrueckii, and Bifidobacterium breve have been shown to reduce Th17 polarization and IL-17 production, while expanding regulatory T cells. A randomized controlled trial in asthma patients showed multi-strain probiotic supplementation significantly reduced Th17-related IL-17 and IL-6.

Three FDA-approved biologics now target IL-17A directly: secukinumab (Cosentyx), ixekizumab (Taltz), and bimekizumab (Bimzelx). If you develop psoriasis, ankylosing spondylitis, or psoriatic arthritis, your AA or AG genotype may predict particularly strong response to these drugs compared to older anti-TNF agents, since IL-17A is the direct driver of your inflammatory phenotype.

Interactions

The rs2275913 promoter variant acts synergistically with rs3748067⁹⁹ rs3748067
another IL17A promoter variant at the +1044C>T position in ulcerative colitis risk. The combination of rs2275913 AA and rs3748067 CC creates a 3.38-fold UC risk, substantially higher than either variant alone. Both should be interpreted together for gut inflammation risk.

The related cytokine gene IL17F rs763780¹⁰¹⁰ IL17F rs763780
F allele reduces IL-17F bioactivity and actually blunts inflammatory signaling — users with the IL-17A risk (rs2275913 A) combined with functional IL-17F (rs763780 GG) have the highest net Th17 output.

Downstream, PTPN22 rs2476601¹¹¹¹ PTPN22 rs2476601
a phosphatase variant that dysregulates T cell activation thresholds interacts with IL-17A pathway variants to compound autoimmune susceptibility — carriers of both should be especially attentive to early autoimmune symptoms.

The vitamin D receptor pathway variants (VDR rs2228570) influence how effectively vitamin D can suppress the NFAT binding at the IL-17A promoter — if VDR function is also impaired, higher vitamin D doses may be needed to achieve equivalent Th17 suppression.

Your body's reproductive clock is partly set by genes long before you are born. Among the loci robustly linked to the timing of natural menopause and the risk of primary ovarian insufficiency (POI) is rs2303369, an intronic variant in the FNDC4¹¹ FNDC4
Fibronectin Type III Domain Containing 4 — a secreted protein structurally related to the exercise myokine irisin gene on chromosome 2. The T allele at this position has been associated with slightly earlier menopause onset across large population studies, and the homozygous TT genotype has shown elevated odds of premature ovarian insufficiency in clinical cohorts.

The Mechanism

FNDC4 encodes a protein belonging to the fibronectin type III domain-containing family — the same structural family as FNDC5/irisin, the well-studied exercise-released myokine. Like irisin, FNDC4's extracellular domain can be proteolytically cleaved and secreted as a circulating factor. Its primary receptor, ADGRF5 (also known as GPR116)²² ADGRF5 (also known as GPR116)
an adhesion G protein-coupled receptor expressed in adipose tissue and the ovary, is present in mouse ovarian tissue, pointing to a direct autocrine or paracrine role in follicular biology.

Recent in vitro and in vivo work has begun to clarify this role: Daudon et al. 2025³³ Daudon et al. 2025
Daudon M, et al. FNDC4 modulates in vitro bovine granulosa and theca cell metabolism and alters follicle development in vivo. Animal Reproduction Science, 2025 showed that FNDC4 increases glucose uptake in granulosa cells, decreases lipid content in theca cells, and — when applied directly to growing follicles in vivo — caused follicle regression, likely through reduced cellular metabolic output.

How exactly the intronic rs2303369 variant alters FNDC4 expression or splicing is not yet established — it is likely a regulatory or tagging variant in linkage disequilibrium with the functional change. The locus also shows pleiotropy⁴⁴ pleiotropy
when a single genetic variant influences multiple seemingly unrelated traits, with nearby variants correlated with kidney function, type 2 diabetes, serum triglycerides, and C-reactive protein, suggesting FNDC4 sits at a broader metabolic-reproductive intersection.

The Evidence

The strongest association evidence comes from Stolk et al. 2012⁵⁵ Stolk et al. 2012
Stolk L, et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nature Genetics, 2012, a meta-analysis of 22 GWAS in 38,968 European women with replication in up to 14,435 additional women. The FNDC4 locus reached genome-wide significance (p = 2 × 10⁻¹²), with each T allele associated with approximately 0.175 years (~2 months) earlier menopause onset. This effect was subsequently included in Day et al. 2015⁶⁶ Day et al. 2015
Day FR, et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, which expanded the menopause GWAS to approximately 70,000 women of European ancestry and identified 54 independent menopause-timing signals.

Clinical cohort data from Mirinezhad et al. 2021⁷⁷ Mirinezhad et al. 2021
Mirinezhad MR, et al. Genetic Determinants of Premature Menopause in A Mashhad Population Cohort. Int J Fertil Steril, 2021 examined 117 women with premature menopause (before age 40) against 183 healthy controls. The TT genotype at rs2303369 was associated with an odds ratio of 2.40 (95% CI 1.13–5.10, p=0.020) for premature menopause under a recessive model. It is notable that this association did not survive Bonferroni correction in the small cohort, and population-level GWAS studies rather than case-control studies provide the more robust evidence base for this locus.

Effect sizes are modest: 0.175 years per allele in the largest meta-analysis. This locus accounts for a small fraction of the total genetic variance in menopause timing, which is estimated to be 50–70% heritable. The practical significance lies in accumulation across multiple loci — women carrying multiple menopause-timing risk variants at independent loci may have meaningfully earlier expected follicle depletion compared to the population average.

Practical Actions

For CC genotype carriers (no T alleles), this locus provides no signal toward earlier follicle depletion. This is the most common genotype globally (~37% of the population) and represents the baseline for this variant.

For CT and TT carriers, each T allele carries a modest signal toward somewhat earlier ovarian aging. The T allele is notably less common in East Asian populations (~13%) compared to European (~39%) and South Asian (~42%) populations, so the population-attributable risk differs substantially by ancestry.

Serum anti-Müllerian hormone (AMH)⁸⁸ anti-Müllerian hormone (AMH)
a hormone secreted by granulosa cells in small growing follicles; the most sensitive and cycle-independent measure of the remaining follicle pool testing provides the most clinically actionable measure of where ovarian reserve actually stands, regardless of genotype. This genetic signal is most useful as context for interpreting AMH results that fall at the lower end of age-specific reference ranges.

Interactions

FNDC4 rs2303369 + MCM8 rs16991615 (dual reproductive aging loci): MCM8 encodes a DNA repair helicase also strongly associated with menopause timing and AMH levels. Women lacking the protective MCM8 A allele (GG genotype) who also carry T alleles at rs2303369 carry independent risk signals from two separate biological pathways — DNA repair helicase insufficiency (MCM8) and follicular metabolic signaling (FNDC4 locus). Whether these effects are strictly additive or interact beyond additivity is not established in published literature, but the combined profile of multiple independently replicated menopause-timing risk alleles at unlinked loci represents a higher prior probability of earlier follicle depletion than either variant alone. A compound action for this combination — emphasizing proactive AMH baseline testing and early fertility timeline discussion — is warranted for women carrying risk alleles at both loci. See related SNP rs16991615.

Note on HELQ locus context: Early GWAS publications and some follow-up studies refer to this chromosomal region as the "HELQ locus" because HELQ (encoding a separate DNA repair helicase on chromosome 4) was among the DNA repair genes highlighted in the pathway analysis of the same 2012 study. The index SNP rs2303369 maps to FNDC4 on chromosome 2 in dbSNP, while the true HELQ index SNP is rs4693089 on chromosome 4. Both were identified in the same landmark GWAS.

CTLA-4 (Cytotoxic T-Lymphocyte Associated Protein 4) is one of the immune system's most powerful brakes. Expressed on activated T cells, it competes with CD28 to bind CD80 and CD86 on antigen- presenting cells — and when CTLA-4 wins, T cell activation is dampened. The rs231775 variant (also called +49A>G or Thr17Ala) sits in the leader peptide¹¹ leader peptide
The signal peptide is a short N-terminal sequence that guides newly synthesised protein into the secretory pathway; it is cleaved from the mature protein of the CTLA-4 protein. This single amino acid change — threonine to alanine at position 17 — affects how efficiently CTLA-4 traffics to the T cell surface, subtly weakening the immune checkpoint and increasing susceptibility to a broad range of autoimmune conditions. With 539 published studies in the literature²² 539 published studies in the literature
Ensembl VEP annotates 539 publications for rs231775, this is among the most intensively studied common autoimmune susceptibility variants.

The Mechanism

CTLA-4 is synthesized with an N-terminal signal peptide that guides it into the endoplasmic reticulum and ultimately to the cell surface. The Thr17Ala substitution changes the glycosylation profile of the leader peptide, altering the efficiency with which the protein is processed and trafficked³³ processed and trafficked
ClinVar expert panel notes flow cytometry data showing Thr17Ala produces cell surface staining comparable to wild-type, while population-level studies document functional immune differences to the plasma membrane. The G allele (Ala17) is associated with reduced CTLA-4 surface density on T cells, meaning fewer inhibitory signals reach the T cell receptor complex. With less CTLA-4 at the surface, the molecular brake on T cell activation is partially released, allowing T cells to respond more vigorously — and potentially to self-antigens they should ignore.

This variant is in partial linkage disequilibrium with the CT60 variant (rs3087243) in the CTLA4 3'UTR, which has an independent effect on mRNA stability. Together, the two variants can compound to lower CTLA-4 expression through complementary mechanisms: reduced surface trafficking (rs231775) and reduced mRNA stability (rs3087243).

The Evidence

The G allele of rs231775 is one of the most replicated common autoimmune susceptibility variants in the human genome. A meta-analysis of 63 published studies⁴⁴ meta-analysis of 63 published studies
Tang et al. 2012, Gene, reviewing data through December 2011 confirmed that the G allele increases type 1 diabetes susceptibility with an odds ratio of 1.47 (95% CI 1.36–1.60, P<0.001), a remarkably consistent signal that held across both Caucasian and Asian populations and all age groups.

For Graves' disease and autoimmune thyroid disease, the association is similarly robust. A meta-analysis of 42 case-control studies⁵⁵ meta-analysis of 42 case-control studies
Si et al. 2013, 8,288 cases and 9,372 controls, predominantly Asian and Caucasian populations found G allele risk across multiple genetic models: additive OR = 1.44 (95% CI 1.32–1.58), dominant OR = 1.62 (95% CI 1.43–1.84), and recessive OR = 1.59 (95% CI 1.40–1.81). The association was significant and consistent across all models tested.

In systemic lupus erythematosus, an updated meta-analysis of 18 studies⁶⁶ updated meta-analysis of 18 studies
Chang et al. 2012, 1,806 SLE cases and 2,490 controls found GG versus AA OR = 1.53 overall, rising to OR = 1.89 in Asian populations. A broader autoimmune meta-analysis⁷⁷ broader autoimmune meta-analysis
Yu et al. 2021, 47 studies involving 11,893 cases and 12,032 controls across AS, RA, and SLE confirmed the G allele significantly elevates risk for rheumatoid arthritis in Caucasian and Mongolian populations.

Practical Implications

Carrying one or two copies of the G allele does not mean you will develop an autoimmune disease — most carriers never do. However, the G allele is a consistent signal of reduced immune checkpoint function, which means your immune system has a somewhat lower threshold for mounting inflammatory responses against self-tissues. The conditions most strongly linked to this variant are Graves' disease, Hashimoto's thyroiditis, type 1 diabetes, and systemic lupus erythematosus.

For those already diagnosed with autoimmune disease, rs231775 G allele status has a practical clinical implication: abatacept (Orencia), a biologic medication that is literally a recombinant CTLA-4 fusion protein⁸⁸ recombinant CTLA-4 fusion protein
Abatacept mimics CTLA-4 by binding CD80/CD86 and blocking T cell costimulation, compensating for the reduced endogenous CTLA-4 activity used in rheumatoid arthritis and other autoimmune conditions, may work especially well for G allele carriers. A retrospective cohort of 109 RA patients found the G allele was associated with an OR of 3.48 for achieving EULAR response at 12 months and OR = 4.68 for low disease activity, suggesting that restoring what the variant reduces — CTLA-4 activity — is particularly effective treatment for those with this genotype.

Women with G allele genotypes should be aware that thyroid autoimmunity (Graves' disease, Hashimoto's) is considerably more common in women and is further elevated by this variant. Annual thyroid function testing (TSH, free T4) is a low-cost, high-yield monitoring strategy for G allele carriers with personal or family history of thyroid disease.

Interactions

The strongest documented epistatic interaction for rs231775 is with MSH5 rs3131379 in systemic lupus erythematosus. A gene-gene epistasis study of 4,248 SLE cases and 3,818 controls⁹⁹ gene-gene epistasis study of 4,248 SLE cases and 3,818 controls
Hughes et al. 2012, identified gene-gene interactions across SLE susceptibility loci and documented epistasis between rs3131379 and rs231775 found the combination of rs3131379 risk allele and rs231775 G allele shows an interaction OR of 1.19 (P=7.8×10⁻⁵), the strongest pairwise epistasis signal in that dataset. This means carriers of both risk alleles face disproportionately higher SLE risk than expected from either variant alone.

Within the CTLA4 locus, the CT60 variant rs3087243 (a 3'UTR regulatory variant) interacts with rs231775 to compound autoimmune susceptibility through independent mechanisms: rs231775 reduces surface trafficking efficiency while rs3087243 reduces mRNA stability. Combined risk alleles at both positions are most common in populations with high autoimmune thyroid disease prevalence.

CTLA4 rs231775 also interacts with PTPN22 rs2476601 (the R620W variant) in determining risk for seropositive autoimmune conditions including RA and type 1 diabetes. Both variants impair the braking mechanisms that prevent T cell activation against self-antigens, and their co-occurrence increases absolute disease risk beyond what either confers individually.

The immune system's ability to distinguish self from non-self depends on an exquisitely precise editing process deep inside every nucleated cell. ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)¹¹ ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)
an enzyme that trims peptides to the optimal 8–10 amino acid length required for loading onto MHC class I molecules before surface display to immune surveillance cells acts as a molecular ruler, measuring and calibrating the peptide repertoire before it reaches the cell surface. The Gln730Glu variant at position 730 of ERAP1 sits in the C-terminal regulatory domain and alters the enzyme's length-selectivity — specifically modulating whether it preferentially trims longer peptides down or terminates trimming at the 9-mer stage. Though subtler in its isolated effect than the better-studied Lys528Arg (rs30187) variant, Gln730Glu completes the major coding variant profile of ERAP1 and is a consistent member of the high-risk CCT haplotype²² CCT haplotype
the three-SNP haplotype at rs27044/rs10050860/rs30187 with alleles C on coding strand (= G plus-strand), C, and T that is associated with approximately 1.8-fold increased AS risk strongly associated with ankylosing spondylitis.

The Mechanism

Position 730 lies in the C-terminal domain of ERAP1, a region that contributes to substrate binding and influences the enzyme's conformational dynamics during the trimming cycle. The Gln730 (Q, G allele on plus strand) residue is present in ERAP1 allotypes 1 and 2 of the naturally occurring haplotype system. Biochemical characterization has shown that allotypes 1 and 2 — those carrying Q730 — display higher enzymatic activity than E730-containing allotypes for 9-mer substrates with hydrophobic C-terminal residues³³ allotypes 1 and 2 — those carrying Q730 — display higher enzymatic activity than E730-containing allotypes for 9-mer substrates with hydrophobic C-terminal residues
the hydrophilic glutamine at 730 is better suited for accommodating substrates with hydrophobic C-termini compared to the negatively charged glutamate in the E730 form. This means Q730 ERAP1 (the G allele, risk) generates a different peptide repertoire than E730 ERAP1 (the C allele, protective): more active trimming of 9-mer substrates, effectively altering the density and identity of short peptides available for MHC class I loading.

The protective effect of the E730 variant (C allele) has been functionally validated at the cellular level. Studies using ERAP1-expressing antigen-presenting cells⁴⁴ Studies using ERAP1-expressing antigen-presenting cells
Zervoudi et al. 2016, Ann Rheum Dis — examining HLA-B27 free heavy chain (FHC) expression in monocytes from AS patients carrying different ERAP1 genotypes demonstrated that the wild-type Q730 ERAP1 (but not the protective K528R or Q730E variants) increases cell surface HLA-B27 free heavy chain expression — a key mediator of AS pathogenesis through NK cell and innate lymphocyte activation. At the receptor level, E730 (C allele) generates suboptimal pHLA-B27 conformers⁵⁵ suboptimal pHLA-B27 conformers
peptide-HLA class I complexes with suboptimal peptide content that bind less efficiently to immune receptors that reduce the affinity of the natural killer cell receptor KIR3DL1 for HLA-B27, weakening the dysregulated NK cell signaling implicated in AS.

The Evidence

Haplotype-level AS risk. The foundational paper establishing ERAP1's role in AS Evans et al. 2009, Wellcome Trust Canadian cohorts⁶⁶ Evans et al. 2009, Wellcome Trust Canadian cohorts
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility identified a three-SNP ERAP1 haplotype (rs27044/rs10050860/rs30187 — CCT in coding-strand notation, where C at rs27044 corresponds to the G allele in plus-strand notation) as a potent risk factor for AS. This CCT risk haplotype showed a pooled odds ratio of 1.81 (95% CI 1.46–2.24, P=7×10⁻⁸) across three independent Canadian cohorts. rs27044 was present as a core member of this haplotype, establishing its role as a risk-conferring component of the high-activity ERAP1 allotype system.

Variant-level AS association. A 2019 meta-analysis of 26 case-control studies pooling 17,223 AS patients and 36,915 controls specifically examined rs27044 and rs30187⁷⁷ specifically examined rs27044 and rs30187
Chen et al. 2019, Association of rs27044 and rs30187 polymorphisms in ERAP1 gene with ankylosing spondylitis and found that the G allele (Q730, risk) was significantly associated with increased AS susceptibility versus the C allele (E730): OR=1.24 (95% CI 1.16–1.33, P<0.001), with the effect present in both Caucasian and Asian populations. This is a well-powered finding, though effect sizes at the individual variant level are more modest than at the haplotype level, reflecting that rs27044 shares variance with its co-inherited haplotype partners.

Five-SNP haplotype architecture. A comprehensive haplotype analysis Casserly et al. 2017, PNAS⁸⁸ Casserly et al. 2017, PNAS
ERAP1 AS association attributable to common genotypes rather than rare haplotype combinations characterizing five common ERAP1 SNPs (M349V, K528R, D575N, R725Q, Q730E) identified the MKDRQ haplotype — which carries Q730 (G allele) — as significantly elevated in AS cases versus controls (33% vs. 27%, P=1.2×10⁻²⁴). This study clarified that AS risk derives from common haplotype combinations rather than unusual rare combinations, and established that the Q allele at position 730 consistently co-occurs with disease-associated variants on the highest-frequency risk haplotype.

Protective mechanism of E730. At the functional level, the Glu730 variant (C allele) has been shown to be protective through two independent mechanisms: reducing HLA-B27 free heavy chain surface expression in AS patient monocytes, and generating suboptimal pHLA-B27 conformers that diminish KIR3DL1 receptor binding on NK cells. Both findings support the conclusion that Q730 (G allele) contributes to AS pathogenesis by maintaining conditions that favor HLA-B27 misfolding and immunostimulatory FHC formation.

Practical Implications

For most carriers of the GC genotype (approximately 41% of people), there is a modestly elevated contribution from the G allele to ERAP1 activity in the context of specific co-inherited haplotypes. The clinical relevance of rs27044 is greatest when: (1) it co-occurs with the risk alleles at rs30187 (K528, T allele) and rs10050860 on the same chromosome, forming the full CCT risk haplotype; and (2) the individual carries HLA-B27, since all known ERAP1 effects on AS are conditional on HLA-B27 positivity.

For GG homozygotes (approximately 8% of the population), both copies of ERAP1 carry Q730, and if this co-occurs with the full CCT risk haplotype and HLA-B27, the risk elevation is substantial. The conditions to monitor for — ankylosing spondylitis and potentially psoriasis — have well-established early warning signs and effective early treatments.

Interactions

rs27044 × rs30187 × rs10050860: CCT risk haplotype for AS. These three ERAP1 coding variants define the most extensively validated disease-risk haplotype at the ERAP1 locus. The CCT combination (G at rs27044 + risk alleles at rs10050860 and rs30187) is associated with OR=1.81 for AS, substantially higher than any individual variant effect. Individuals who are homozygous for this haplotype (inheriting CCT from both parents) face the highest ERAP1-attributable AS risk in the population. This is a strong candidate for a compound action at the rs27044 + rs30187 level (the two most commonly genotyped variants in the haplotype).

rs27044 × HLA-B27: Conditional epistasis. Like all ERAP1 coding variants, rs27044's contribution to AS risk operates through its effect on the peptide repertoire available to HLA-B27. The mechanistic evidence (FHC reduction, suboptimal pHLA conformers) directly links Q730 to dysregulated HLA-B27 biology. In HLA-B27-negative individuals, ERAP1 variants including rs27044 do not show a detectable AS association — making HLA-B27 status the key modifier of this variant's clinical significance.

rs27044 × rs26653 (Arg127Pro): Third ERAP1 allotype determinant. rs26653, rs30187, and rs27044 together define the major functional allotype classes of the ERAP1 enzyme. The full allotype classification is needed for accurate interpretation: the risk haplotype carries Arg127 (rs26653 C allele, coding strand), Lys528 (rs30187 C allele), and Gln730 (rs27044 G allele, plus strand), while the protective haplotype carries combinations including Glu730 (E allele, rs27044 C allele).

Your blood contains a molecular scissors called ADAMTS13¹¹ ADAMTS13
A Disintegrin and Metalloproteinase with Thrombospondin motifs 13, a protease whose sole critical job is to cut ultra-large von Willebrand factor (VWF) multimers into smaller, manageable pieces. Without this cleavage, VWF multimers accumulate in circulation and on vessel walls, triggering spontaneous platelet aggregation that can cause dangerous microvascular blockages. The rs28647808 variant in the ADAMTS13 spacer domain substitutes proline for alanine at position 618, reducing how efficiently the enzyme is secreted and how actively it cleaves VWF — with consequences that become clinically significant when kidneys are already under metabolic stress from type 2 diabetes.

The Mechanism

The spacer domain of ADAMTS13 (residues 556–685) is essential both for recognizing and binding VWF and for maintaining proper protein folding and secretion. Position 618 sits within the β6–β7 loop of this domain, adjacent to an N-linked glycosylation site at residue 614 that is important for protein stability. The Pro618→Ala substitution replaces a medium-size hydrophobic residue (proline) with a small hydrophobic residue (alanine), altering the loop's geometry and reducing both protease secretion and VWF-cleaving activity — as confirmed in cell-expression studies where the Ala618 protein showed measurably lower proteolytic output than the wild-type Pro618 protein.

The result is a partial, inherited reduction in ADAMTS13 function. This has limited consequences in healthy vasculature, where only modest ADAMTS13 activity is needed to keep VWF multimers in check. But in type 2 diabetes — where chronic hyperglycemia damages endothelial cells, increases VWF release, and promotes a hypercoagulable milieu — even a partial reduction in ADAMTS13 function can tip the balance toward intra-capillary thrombosis. The renal microvasculature, with its high surface area and filtration demands, is especially vulnerable to this mechanism.

The Evidence

The central evidence comes from the BENEDICT trial²² BENEDICT trial
BErgamo NEphrologic DIabetes Complications Trial Phase A — a randomized controlled trial of 1,163 normoalbuminuric type 2 diabetic patients genotyped for Pro618Ala and randomized to ACE inhibitor (trandolapril) or non-ACEi therapy. Ala carriers (about 17% of patients, matching Hardy-Weinberg expectations for an ~8.8% G allele frequency in Europeans) had dramatically different outcomes depending on treatment:

• Ala carriers without ACEi: HR 8.50 (95% CI 2.42–29.96) for new-onset microalbuminuria (renal events) relative to Ala carriers on ACEi
• Ala carriers with ACEi: completely protected — outcomes indistinguishable from the low-risk reference group
• Pro/Pro homozygotes without ACEi: HR 4.77 (95% CI 1.48–15.36) — elevated but well below the Ala carrier risk
• Interaction p-value: 0.019 for renal events; 0.014 for combined renal/cardiovascular events

A substudy of 487 patients³³ substudy of 487 patients
Rurali et al., Diabetes 2013 confirmed the mechanistic link: Ala carriers had significantly lower serum ADAMTS13 activity than Pro/Pro homozygotes, and ADAMTS13 activity was inversely correlated with renal events (r = −0.326, p = 0.027), cardiovascular events (r = −0.351, p = 0.026), and combined events (r = −0.288, p = 0.009). Among Ala carriers, ACEi therapy significantly raised ADAMTS13 activity — no such effect was seen in Pro/Pro homozygotes — suggesting that ACEi may enhance ADAMTS13 bioavailability by reducing the competition between ADAMTS13 and the hypercoagulable environment induced by angiotensin-II signaling.

A smaller cross-sectional study of 86 type 2 diabetics⁴⁴ smaller cross-sectional study of 86 type 2 diabetics
Taniguchi et al., Thromb Res 2010 found significantly lower ADAMTS13 antigen levels in patients with overt nephropathy versus normoalbuminuric patients, and a positive correlation between the VWF/ADAMTS13 ratio and carotid intima-media thickness — reinforcing the link between impaired VWF proteolysis and vascular damage in diabetic disease.

Mendelian randomization analyses⁵⁵ Mendelian randomization analyses
Ye and Zheng, Front Genetics 2021 using large GWAS datasets (5,448 individuals for ADAMTS13 activity; up to 337,000 for cardiovascular outcomes) found that lower ADAMTS13 activity — not merely lower protein levels — is causally associated with higher risks of coronary heart disease (β = −0.0041, p = 0.037) and myocardial infarction (β = −0.0048, p = 0.027), providing genetic-causal support for the protein's role across the cardiovascular spectrum.

Importantly, a study in chronic coronary disease patients without diabetes (MASS II trial, n=560⁶⁶ MASS II trial, n=560
PMID 19427680) found no independent association between Pro618Ala and cardiovascular events, suggesting the variant's risk may be specifically expressed in the context of diabetic vascular injury rather than being a universal cardiovascular risk factor.

Practical Actions

For the roughly 83% of people who carry two wild-type Pro618 alleles, ADAMTS13 function is at its highest genetically-determined level, and no specific action is needed beyond standard cardiovascular care.

For Ala carriers — especially those with type 2 diabetes — the evidence from BENEDICT has a clear clinical implication: ACE inhibitors appear to provide genotype-specific protection that goes beyond their standard reno- and cardioprotective effects. If you carry the Ala allele and have diabetes, early and consistent ACEi therapy may be particularly important for preserving kidney function. This doesn't override other considerations (allergies, cough, potassium levels, kidney function), but it adds a pharmacogenomic argument for ACEi preference over other antihypertensive classes when clinical choice exists.

Monitoring ADAMTS13 activity directly (via functional plasma assay) is technically possible but not standard clinical practice. Monitoring renal function closely — microalbuminuria screening annually — gives a practical early-warning window for the intrarenal thrombosis that the mechanism predicts.

Interactions

The ADAMTS13 Pro618Ala effect is strongly modulated by metabolic context: the variant shows its most pronounced phenotype in type 2 diabetes, where hyperglycemia amplifies VWF release from endothelial cells and creates the substrate overload that reduced ADAMTS13 activity cannot handle. Outside of diabetic vascular disease, the variant appears clinically silent for cardiovascular endpoints.

Von Willebrand factor level-raising variants (e.g., ABO blood group locus SNPs that affect VWF clearance, or VWF gene variants) represent a plausible interaction class — elevated VWF combined with reduced ADAMTS13-mediated cleavage would compound the prothrombotic burden — though direct genotype × genotype evidence for Pro618Ala plus VWF variants has not been formally studied.

The mineralocorticoid receptor (MR), encoded by NR3C2, is far more than a blood-pressure sensor. It binds aldosterone and cortisol to coordinate sodium retention, potassium excretion, and fluid homeostasis in the kidneys — but the same receptor is also expressed in the uterus, placenta, and vascular endothelium, where it plays an underappreciated role in implantation, endometrial receptivity, and the cardiovascular adaptations of pregnancy. rs2883929 sits in intron 3 of NR3C2 on chromosome 4 and is one of two intronic variants in this gene identified in a 2015 case-control study as significantly associated with spontaneous preterm birth¹¹ spontaneous preterm birth
birth before 37 completed weeks of gestation, affecting 5–10% of pregnancies globally. The minor G allele (~21% globally) shows a loss of the protective effect carried by the common A allele.

The Mechanism

Intronic variants in NR3C2 can influence MR expression levels through effects on [pre-mRNA splicing, intronic enhancers, or regulatory RNA elements | Approximately 94% of multi-exon human genes undergo alternative splicing; intronic variants can alter splice-site strength, create cryptic splice sites, or disrupt splicing regulatory sequences without directly changing the protein sequence]. rs2883929 has no direct protein-change consequence, but the gene sits on the minus strand of chromosome 4 (GRCh38 position 148,299,957), and the regulatory landscape in NR3C2 intron 3 is rich with transcription factor binding sites and histone modification marks.

During normal pregnancy, the MR pathway undergoes dramatic shifts: plasma aldosterone rises 3- to 10-fold in the first trimester, driven by progesterone and human chorionic gonadotropin, to support expanded plasma volume and uterine blood flow. The MR in uterine decidual cells and the trophoblast modulates inflammatory signaling, vascular tone, and cellular invasion during implantation and early placentation. [Altered MR expression or sensitivity in these tissues | Whether through changes in receptor density, ligand affinity, or downstream signaling coupling] could disrupt the tightly regulated decidualization program and placental vascular remodeling, creating conditions that predispose to preterm labor.

A distinct mechanism operates through the vascular endothelium. A 2022 mouse study demonstrated that endothelial MR activation mediates leptin-driven preeclampsia-like pathology²² endothelial MR activation mediates leptin-driven preeclampsia-like pathology
Features including maternal hypertension, impaired spiral artery remodeling, fetal growth restriction, and endothelial dysfunction were all prevented by endothelial-specific MR deletion. Similarly, a 2020 study identified an NR3C2 alternative splicing variant enriched in preeclamptic placentas that impairs endothelial proliferation, migration, and tube formation, directly linking aberrant MR isoforms to the endothelial dysfunction characteristic of preeclampsia³³ preeclampsia
a pregnancy complication involving new-onset hypertension after 20 weeks, affecting 3–5% of pregnancies and a leading cause of maternal and neonatal morbidity.

The Evidence

The primary evidence for rs2883929 comes from a prospective case-control study of 190 women with spontaneous preterm birth and 369 term-delivery controls from the SCOPE cohort in Perth, Australia⁴⁴ prospective case-control study of 190 women with spontaneous preterm birth and 369 term-delivery controls from the SCOPE cohort in Perth, Australia
Christiaens et al., BMC Medical Genetics, 2015. Researchers genotyped 16 SNPs in stress-response genes (NR3C1, NR3C2, CRHR1, CRHR2) chosen for their role in the HPA axis and maternal stress response. Two NR3C2 variants passed significance after adjustment for maternal age, smoking, alcohol use, educational status, and miscarriage history: rs17484063 (OR 0.50, p = 0.038) and rs2883929 (OR 0.49, p = 0.017). The OR less than 1 indicates that the common A allele is associated with lower preterm birth odds; conversely, G allele carriers lose this protective effect and show risk approaching the population baseline.

The study is replicated biologically by mechanistic evidence. [NR3C2 genetic variants associate with aldosterone levels, blood pressure, and salt sensitivity in population cohorts | Heydarpour et al. JCEM, 2024; Wang et al. J Clin Hypertension, 2025], with effects modulated by sex and age. In Caucasian women under 50, the aldosterone elevation conferred by NR3C2 risk variants is substantially greater, suggesting estrogen-MR interactions amplify the receptor's sensitivity during reproductive years — the exact developmental window when pregnancy adaptations must occur.

The evidence is classified as moderate: the preterm birth finding comes from a single study of 559 participants, the mechanism is biologically plausible but not fully characterized, and the OR (0.49) is substantial but derived from a modest sample. Larger replication cohorts are needed.

Practical Implications

For people carrying one or two copies of the G allele, the clinical implications center on awareness during pregnancy planning and proactive blood pressure monitoring during gestation. The MR pathway regulates both fluid homeostasis and vascular tone; variants that alter MR function may affect how well the vasculature adapts to the physiological demands of pregnancy.

Sodium and potassium balance are directly under MR regulation. The same receptor that influences preterm birth risk also governs how the body responds to dietary salt: NR3C2 variants associate with salt-sensitive blood pressure responses, meaning G allele carriers may be more susceptible to blood-pressure elevation under high-sodium intake, particularly during the hemodynamic demands of pregnancy.

Interactions

rs17484063 is the second NR3C2 intronic variant identified alongside rs2883929 in the preterm birth association study, with OR 0.50 (p = 0.038). Both variants lie in introns of the same gene and may be in partial linkage disequilibrium. Carrying the minor alleles at both loci simultaneously has not been formally studied but could reflect a compound NR3C2 regulatory haplotype with additive effects on MR expression.

rs1799998 (CYP11B2 -344C>T): CYP11B2 encodes aldosterone synthase, the enzyme that produces aldosterone — the primary ligand for the MR. Variants in CYP11B2 that increase aldosterone production would amplify the signal received by the MR encoded by NR3C2. Carrying risk variants at both genes may compound aldosterone-driven blood pressure effects during pregnancy, though formal gene-gene interaction data are not published.

rs2070951 (NR3C2 functional SNP): this coding-region NR3C2 variant has been associated with postpartum depression risk through a gene-hormone interaction with placental CRH levels, suggesting NR3C2 variants collectively influence multiple pregnancy-related outcomes through HPA axis modulation.

PSCA¹¹ PSCA
Prostate stem cell antigen — despite the name, this GPI-anchored glycoprotein is broadly expressed across epithelial tissues including bladder urothelium, gastric mucosa, and pancreatic ducts; it belongs to the Ly-6/uPAR superfamily and regulates cell adhesion, proliferation, and the mucosal response to bacteria lines the inner surface of the bladder and is thought to help maintain urothelial integrity against bacterial attachment. The rs2976388 variant sits deep within an intron of the PSCA gene at chromosome 8, position 142,678,838 (GRCh38). It does not change the protein sequence, but it lies within a region of active regulatory chromatin — specifically within enhancers defined in epidermal and epithelial keratinocytes — and is in strong linkage disequilibrium²² linkage disequilibrium
LD — the tendency of nearby variants to be inherited together; high LD means the two SNPs almost always occur together on the same chromosome, so one serves as a reliable proxy for the other with rs2294008, a functional variant in the PSCA 5′ UTR with established effects on gene expression.

The Mechanism

The G allele at rs2976388 tags a regulatory haplotype that influences PSCA expression in epithelial tissues. The variant overlaps strong enhancer marks in urothelial keratinocyte epigenome data, suggesting it may modulate enhancer activity in the bladder epithelium. Because rs2976388 is in tight LD with rs2294008 — the variant that creates a YY1 repressor binding site suppressing PSCA transcription — carrying the rs2976388 G allele effectively marks the same suppressive haplotype at the PSCA locus. Less PSCA on the urothelial surface may impair the epithelial barrier that normally restricts bacterial adherence. The female-specificity of the UTI association (see below) is biologically coherent: women have a substantially shorter urethra and a higher anatomical exposure of the bladder to gut-origin uropathogens, making urothelial surface molecule expression a more decisive factor in bacterial containment than in men.

PSCA's role in peptic ulcer disease — also associated with this variant (OR 1.09 for the G allele) — reinforces the gene's function across epithelial barrier tissues and suggests a shared mechanism of reduced surface PSCA compromising mucosal protection in both the stomach and bladder.

The Evidence

The primary association was established in a 23andMe genome-wide study³³ 23andMe genome-wide study
Tian C et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nature Communications, 2017 of 23 infection phenotypes in over 200,000 individuals of European ancestry. For urinary tract infection frequency, rs2976388 reached genome-wide significance with a beta of 0.04 and p = 3.27 × 10⁻¹⁰. Crucially, when the authors stratified by sex, the association was highly significant in women (P < 1 × 10⁻¹¹) but completely absent in men (P > 0.1) — a sex-specific effect with a difference of more than ten orders of magnitude in statistical evidence. This pattern is consistent with the known epidemiology of UTI: uropathogenic E. coli infections are approximately 30-fold more common in women than men, and urothelial surface antigen expression is a plausible modifier of that pre-existing anatomical vulnerability.

A second independent GWAS for peptic ulcer disease⁴⁴ GWAS for peptic ulcer disease
Wu et al. GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nature Communications, 2021 identified the same G allele at rs2976388 with OR 1.09 and p = 2 × 10⁻¹⁴, extending PSCA's role as a shared mucosal vulnerability gene across gastroduodenal and urological epithelia.

For the closely linked rs2294008 and rs2978974 variants (bladder cancer), a PNAS study⁵⁵ PNAS study
Fu YP et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. PNAS, 2012 showed that the PSCA risk haplotype increases PSCA mRNA expression in bladder tumour tissue and independently confers bladder cancer susceptibility. Because rs2976388 tags the same haplotype block, it is co-inherited with both the UTI and bladder cancer risk signals at this locus.

Practical Implications

For women with the GG or AG genotype, the clearest interventions are those that reduce uropathogen adherence to the urothelium. The mechanistic basis of D-mannose is direct: it saturates the FimH lectin⁶⁶ FimH lectin
The tip adhesin of type 1 pili on uropathogenic E. coli; FimH binds mannose residues on urothelial uroplakin proteins; free D-mannose competes for binding and prevents bacterial attachment to the bladder wall on uropathogenic E. coli, preventing the bacteria from anchoring to bladder wall glycoproteins. In an RCT of 308 women⁷⁷ RCT of 308 women
Kranjčec B et al. D-mannose powder for prophylaxis of recurrent urinary tract infections in women. World J Urol, 2014, daily D-mannose reduced recurrent UTI from 60.8% to 14.6% over six months — a result comparable to continuous nitrofurantoin prophylaxis but without antibiotic resistance consequences.

Cranberry A-type proanthocyanidins (PACs) provide a complementary anti-adhesion mechanism targeting P-fimbriated E. coli (distinct from the FimH pathway). A meta-analysis⁸⁸ meta-analysis
Fu Z et al. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women. J Nutrition, 2017 of 7 RCTs (1,498 women) found a 26% reduction in UTI recurrence (pooled RR 0.74, 95% CI 0.55–0.98). High-dose standardized cranberry extract (36 mg PACs daily) is more consistently effective than cranberry juice, which contains highly variable PAC concentrations.

Interactions

The rs2976388 G allele is in strong linkage disequilibrium with rs2294008 (PSCA 5′ UTR), the functional variant that suppresses PSCA expression through YY1 repressor recruitment. Individuals carrying the G allele at rs2976388 very likely also carry the T allele at rs2294008. Users who appear in both the innate-immunity category (this SNP) and the gut-digestive category (rs2294008) are carrying the same underlying risk haplotype; the rs2294008 entry covers gastric cancer and H. pylori implications in detail, while this entry focuses on the urothelial manifestation.

The second bladder cancer signal at rs2978974 (PSCA intron 2) contributes a multiplicative effect on bladder cancer risk that is independent of rs2294008, per the Fu et al. 2012 PNAS analysis. The UTI phenotype was mapped specifically to rs2976388 in the Tian et al. 2017 GWAS; whether rs2978974 similarly modifies UTI risk has not been tested.

The chromosome 6p21.33 locus is one of the most gene-dense and immunologically consequential stretches in the human genome. Wedged between the classical HLA genes and the complement cascade genes C2 and CFB lies the HLA class III region¹¹ HLA class III region
The central segment of the major histocompatibility complex, encoding complement proteins, heat shock proteins, cytokines like TNF-α, and DNA repair enzymes — an evolutionary hub for immune function, and within it, MSH5 (MutS Homolog 5). MSH5 is a DNA mismatch repair protein that forms an obligate heterodimer with MSH4 and plays a specialized role in two critical immune processes: meiotic crossover and immunoglobulin class-switch recombination²² meiotic crossover and immunoglobulin class-switch recombination
Class-switch recombination is the molecular process by which B cells swap immunoglobulin constant regions, changing from IgM to IgG, IgA, or IgE antibodies; MSH5/MSH4 ensures this DNA rearrangement proceeds through classical repair rather than error-prone microhomology pathways. The rs3131379 variant is an intronic SNP that tags a broader haplotype block carrying risk for systemic lupus erythematosus, with documented epistatic interactions with both IRF5 and CTLA4 — two of the most important non-HLA autoimmune susceptibility genes.

The Mechanism

Rs3131379 lies within an intron of MSH5 and does not itself alter protein sequence. Its biological significance comes from its position as a haplotype tag³³ haplotype tag
A variant in strong linkage disequilibrium with one or more functional variants; genotyping rs3131379 effectively captures the disease-associated haplotype even without knowing the precise causal change for an HLA class III risk haplotype. The A allele marks a chromosomal block containing the complement factor B locus (CFB), C2, and flanking regulatory elements that influence both innate immune complement activation and type I interferon tone. Functional evidence shows that rs3131379 contributes to IFN-α production⁴⁴ IFN-α production
Type I interferons are antiviral cytokines that also drive lupus pathology when chronically elevated; the rs3131379 A allele increases TLR7/8- and TLR9-dependent IFN-α and IFN-β responses in peripheral leukocytes by peripheral leukocytes stimulated through Toll-like receptors 7, 8, and 9 — the same innate immune receptors implicated in lupus pathogenesis through sensing endogenous nucleic acids released from dying cells.

At the molecular level, MSH5 dysfunction impairs immunoglobulin class switching. When MSH5 is working optimally, B cells switch efficiently from IgM to downstream isotypes (IgG, IgA, IgE) using classical DNA repair at the switch junctions. When MSH5 variants impair MSH4 binding — as documented for the L85F/P786S allele at this locus — switch joints accumulate increased microhomology-mediated repair errors⁵⁵ increased microhomology-mediated repair errors
Alternative recombination that uses short regions of sequence similarity rather than canonical break-and-rejoin repair; this produces abnormal junction sequences and is elevated in patients with CVID and IgA deficiency, reducing IgA production efficiency. Patients with IgA deficiency and common variable immunodeficiency (CVID) are enriched for variants at this locus, though the MSH5 variant marks the HLA-DRB1*0102 haplotype rather than directly causing disease.

The Evidence

The strongest SLE-specific evidence comes from a landmark epistasis study by Hughes et al. (2012) examining 4,248 SLE patients and 3,818 healthy controls⁶⁶ Hughes et al. (2012) examining 4,248 SLE patients and 3,818 healthy controls
All European ancestry; the largest published analysis of gene-gene interactions in SLE at the time of European descent. This analysis identified rs3131379 as producing the most significant gene-gene interaction in lupus genetics: the HLA region A allele at rs3131379 interacts with CTLA4 rs231775 with an interaction odds ratio of 1.19 (P = 7.8×10⁻⁵, FDR ≤0.05). The IRF5 interaction was also significant — carrying the rs3131379 A allele increased the odds of also carrying the IRF5 risk allele by 16% (P = 0.0047), suggesting co-segregation or selective pressure maintaining both risk haplotypes together.

Independently, Fernando et al. (2012) performed transancestral high-density mapping⁷⁷ Fernando et al. (2012) performed transancestral high-density mapping
Custom Illumina chip genotyping of the MHC region in 1,433 SLE cases and 1,458 controls from UK, Spanish, and Filipino populations of the entire MHC region in SLE and identified MSH5 as a new susceptibility locus independent of HLA-DRB1 alleles and other known HLA risk factors. This transancestral confirmation across three ancestry groups strengthens the causal attribution to the MSH5 region rather than treating it purely as LD with classical HLA alleles.

Functional validation came from a cardiovascular genetics study that incorporated SLE-derived SNPs to examine interferon regulation. Nelson et al. (2015) identified rs3131379 as one of three variants⁸⁸ Nelson et al. (2015) identified rs3131379 as one of three variants
The three-SNP panel: rs10516487 (TNFAIP3 region), rs3131379 (MSH5/HLA-III), and rs7574865 (STAT4) collectively account for 27.8% of variation in the CpG-oligonucleotide-induced IFN-α response forming a three-SNP genetic risk score that explains 27.8% of variation in TLR-dependent IFN-α production — the highest explained variance from any small SNP panel for this trait. Rs3131379 was associated with TLR7/8- and TLR9-dependent interferon responses, directly connecting the variant to the endosomal RNA/DNA sensing pathway that drives lupus nephritis and other organ manifestations.

A genome-wide association study of cutaneous lupus erythematosus⁹⁹ cutaneous lupus erythematosus
A subset of lupus presentations that primarily affects skin; shares HLA region risk architecture with systemic SLE further identified MHC region signals spanning MICA, MICB, MSH5, TRIM39, and RPP21, consistent with the MSH5 block being a genuine susceptibility region for lupus manifestations across tissue compartments.

Practical Implications

Carriers of the rs3131379 A allele, particularly heterozygotes (AG), should understand that this variant contributes to moderately elevated interferon tone and increased lupus susceptibility, but does not predetermine disease. The A allele is relatively common in European populations (~12%) and rare in East Asian populations (<0.1%), explaining some of the population-specific differences in SLE prevalence patterns. When the rs3131379 A allele co-occurs with IRF5 risk alleles (rs10488631-C or rs2004640-T), the combined effect exceeds either variant alone due to the documented epistatic amplification. Monitoring for lupus symptoms should be prioritized over passive observation when multiple risk alleles are present.

The IgA and antibody class-switching dimension of MSH5 adds a second clinical angle. People carrying A alleles at this locus may have modestly less efficient IgA production — potentially relevant to mucosal immunity, gut immune defense, and IgA nephropathy susceptibility — though this aspect requires further population-level study to quantify.

Interactions

The most important documented interaction is with IRF5 rs10488631. The Hughes 2012 epistasis study found that carrying the MSH5/HLA-III risk allele (rs3131379-A) increases the odds of also carrying the IRF5 risk haplotype (rs2070197, in LD with rs10488631-C) by approximately 16%. This co-occurrence amplifies type I interferon output beyond what either variant contributes independently. IRF5 drives interferon gene transcription while the HLA class III haplotype tagged by rs3131379 appears to lower the threshold for innate immune TLR activation through complement pathway dysregulation and MSH5-mediated effects on B cell antibody diversification.

The second major interaction is with CTLA4 rs231775. CTLA4 is a negative regulator of T cell activation; the rs231775 A allele reduces CTLA4 expression, allowing excessive T cell activation. The interaction OR of 1.19 between rs3131379 and CTLA4 rs231775 suggests that when both the innate immune arm (HLA class III / interferon) and the adaptive T cell arm (CTLA4 checkpoint failure) are genetically compromised, lupus risk compounds in a non-additive manner. This epistatic architecture implies that abatacept (a CTLA4-Ig fusion protein that mimics CTLA4 checkpoint function) might be particularly relevant for patients carrying both risk alleles.

When your skin stretches rapidly — during growth spurts, pregnancy, or weight change — the dermal connective tissue can tear, producing striae distensae¹¹ striae distensae
the medical term for stretch marks, caused by rupture of elastic fibers and reorganization of collagen in the dermis. Whether you develop visible stretch marks depends partly on your genes. The SRPX gene encodes a sushi-repeat-containing protein²² sushi-repeat-containing protein
a class of extracellular proteins with complement control protein (CCP) domains, also called sushi domains, that mediate protein-protein interactions in the extracellular matrix expressed in multiple tissues and localized to the collagen-containing extracellular matrix. rs35318931 changes a serine to phenylalanine at position 413, and carriers of this variant are significantly less likely to develop stretch marks.

The Mechanism

SRPX sits on the X chromosome at Xp21.1 and encodes a 464-amino-acid transmembrane protein with three sushi domains³³ sushi domains
compact ~60 amino acid modules that form protein interaction surfaces; found in complement factors, selectins, and extracellular matrix proteins in its N-terminal region. The protein is predicted to function as an extracellular matrix structural constituent⁴⁴ extracellular matrix structural constituent
proteins that contribute to the physical scaffolding of tissues, including collagen, elastin, and fibrillin and localizes to the collagen-containing extracellular matrix. It has also been characterized as a peroxiredoxin-like protein⁵⁵ peroxiredoxin-like protein
a class of antioxidant enzymes that reduce hydrogen peroxide and organic hydroperoxides with tumor-suppressor activity, capable of inducing apoptosis through caspase-12/9/3 activation.

The rs35318931 variant replaces serine (small, polar) with phenylalanine (large, aromatic)⁶⁶ serine (small, polar) with phenylalanine (large, aromatic)
BLOSUM62 score of -2 indicates an unfavorable substitution from a conservation standpoint, yet the variant is common in Europeans at ~8% allele frequency. This position is conserved across mammalian orthologs (mouse and rat maintain serine), suggesting functional importance. The exact mechanism by which this amino acid change protects against stretch marks remains unknown, but given SRPX's localization to collagen-containing extracellular matrix, the variant may alter how the protein interacts with dermal structural fibers — potentially strengthening elastic microfiber networks that resist tearing under mechanical stress.

Because SRPX is on the X chromosome, males are [hemizygous | having only one copy of a gene, as occurs with X-linked genes in males (XY)] — they carry either G or A, with no heterozygous state. Females can be GG, AG, or AA. This means the variant's protective effect may be more pronounced in males, where a single copy determines the phenotype without the buffering effect of a second allele.

The Evidence

Tung et al. (2013)⁷⁷ Tung et al. (2013)
Genome-wide association analysis implicates elastic microfibrils in the development of nonsyndromic striae distensae. J Invest Dermatol 133:2628-2631 conducted the first GWAS for stretch marks, surveying 33,930 unrelated 23andMe customers of European descent (13,068 cases, 20,862 controls). rs35318931 reached genome-wide significance with P = 1.1 x 10^-13 and an odds ratio of 0.82 (95% CI: 0.77-0.86), meaning A allele carriers had an 18% reduced risk of developing stretch marks. The association replicated in a validation cohort of 4,967 pregnant women for striae gravidarum (P = 0.026, beta = -0.067).

The study identified four genome-wide significant loci in total: rs7787362 near ELN⁸⁸ ELN
the elastin gene, encoding the primary component of elastic fibers in skin, rs35318931 in SRPX, rs10798036 in HMCN1⁹⁹ HMCN1
hemicentin-1, a large extracellular matrix protein related to fibulin, and rs7594220 near TMEM18. Three of the four loci implicate extracellular matrix and elastic microfiber biology, reinforcing the hypothesis that stretch marks arise from genetically determined variation in dermal connective tissue resilience.

UniProt classifies the Ser413Phe substitution as likely benign or benign (LB/B)¹⁰¹⁰ likely benign or benign (LB/B)
functional prediction tools (SIFT: tolerated; PolyPhen-2: possibly damaging) give mixed signals, but the variant's high frequency in Europeans argues against pathogenicity. This is consistent with its role as a common protective variant rather than a disease-causing mutation.

SRPX was originally identified through its deletion in patients with X-linked retinitis pigmentosa¹¹¹¹ deletion in patients with X-linked retinitis pigmentosa
Meindl et al. 1995 found SRPX deleted in RP patients, though subsequent screening of 34 XLRP families found no further mutations, and RPGR was later identified as the primary RP3 gene. While the retinitis pigmentosa link was not confirmed, the deletion studies established SRPX as a real, expressed gene with tissue-specific functions. More recently, SRPX has emerged as a tumor suppressor — SRPX knockout mice develop tumors at a 30% rate¹²¹² SRPX knockout mice develop tumors at a 30% rate
including lymphoma, lung cancer, hepatoma, and sarcoma — adding another dimension to this gene's functional significance.

Practical Actions

The A allele at rs35318931 is protective: carriers are less likely to develop stretch marks during periods of rapid skin stretching (puberty, pregnancy, weight fluctuations, muscle building). If you carry the G allele (reference, non-protective), you have the standard population risk for stretch marks. This is especially relevant during pregnancy, where striae gravidarum affect 50-90% of women.

While genetics loads the gun, environmental factors pull the trigger. Regardless of genotype, maintaining skin hydration and elasticity through appropriate skincare can modulate stretch mark risk. For those with the GG genotype (or hemizygous G in males), proactive measures during high-risk periods may help compensate for the absence of SRPX-mediated protection.

Interactions

rs35318931 sits within a network of extracellular matrix genes that collectively determine skin connective tissue resilience. The same GWAS identified rs7787362 near ELN (elastin) as the strongest stretch mark locus, and rs10798036 in HMCN1 (hemicentin-1) as a third hit. These genes encode different components of the dermal extracellular matrix: elastin provides elastic recoil, hemicentin stabilizes basement membranes, and SRPX contributes to the collagen-containing matrix scaffold. Individuals carrying protective alleles at multiple loci likely have the most resilient dermal connective tissue.

MMP1 (rs1799750), already in the GeneOps database, encodes matrix metalloproteinase 1 (collagenase-1), the primary enzyme that degrades fibrillar collagen in skin. MMP1 activity and SRPX matrix function represent opposing sides of the same biology: collagen remodeling versus collagen stability. An interaction between high-activity MMP1 variants and the non-protective SRPX G allele could compound stretch mark susceptibility, though this specific combination has not been tested in published studies.